What a Lyme ELISA can show
The first result is easy to misread. Testing too early can give a negative result. A positive final result can come from an infection months or years ago because antibodies remain in the blood. Read both tests with the illness date, tick exposure, current signs, and any past Lyme diagnosis or treatment.
Antibody target
Antibodies to the bacteria that cause Lyme disease
The blood test finds the body's response to Borrelia. It does not count the bacteria.
When the algorithm helps
Both test steps during a matching illness
The algorithm can support Lyme disease when exposure, objective signs, timing, and both tiers agree.
What one index cannot show
One number cannot date the infection
Early negatives, cross-reactions, prior antibodies, and assay differences can all change what the report means.
A reactive first-tier ELISA calls for the second test, not for antibiotics, herbs, supplements, or a restrictive diet.
Save this test
Save the full algorithm, not one ELISA line
Keep both test steps with the timing, exposure, past Lyme history, treatment, current findings, repeat plan, and next decision.
My Fog saves the results and questions you enter. A clinician must decide whether the result fits a current or past infection.
What age, pregnancy, and immune health change
The cutoff does not change by age or sex. Read the result with the person's tick exposure, symptoms, past Lyme results, pregnancy, and immune health.
Children and teenagers
Children can have a typical expanding rash, facial weakness, headache, fever, or a swollen knee. A compatible erythema migrans rash in an endemic setting may be diagnosed clinically because early antibodies can be absent. When a child or teenager needs testing, use the same FDA-cleared two-tier algorithm, with no child-only cutoff. Judge symptoms without adult stereotypes.
Pregnancy and breastfeeding
Pregnancy uses the same two-step testing and cutoff. Get prompt care for a matching rash, fever, facial weakness, heart symptoms, or joint swelling. Tell the clinician about pregnancy or breastfeeding because it can change treatment choices.
Men and women
Use the same approved assay pair and reporting rule. Large US datasets show testing and positive rates differ by sex, but those differences may reflect tick exposure, care seeking, clinical practice, or biology. They do not justify different male or female targets or make an IgM-only result reliable after 30 days.
Older adults
Prior positive results and repeat testing become more common with age. A new positive antibody report may show older exposure and give no new explanation for confusion, fatigue, pain, or brain fog. Compare earlier reports and look directly for the current neurologic, cardiac, skin, or joint presentation.
Immune suppression and antibody treatment
B-cell-depleting therapy, immune deficiency, transplant care, early antibiotics, blood products, or immunoglobulin treatment can complicate antibody interpretation. Use infectious-disease or specialist input when the clinical stakes are high and the routine two-tier result does not fit.
Before a Lyme ELISA or EIA blood test
Confirm the reason for testing. Useful questions include an atypical expanding rash, facial weakness, meningitis-like symptoms, nerve-root pain, a new heart-conduction problem, or a swollen large joint after plausible blacklegged-tick exposure. Brain fog or fatigue alone gives the test less useful context.
Get a typical expanding erythema migrans rash checked without waiting for antibodies. CDC and IDSA guidance allows a clinical diagnosis when the rash and exposure setting fit because early serology can still be negative.
Ask which two-step method the laboratory will use. Standard testing uses a first EIA, then IgM and IgG immunoblots when needed. Modified testing uses two different FDA-cleared antibody tests. A positive or unclear first result is not complete until the second test is done.
Bring the tick bite and removal dates, if known. Add where the exposure happened, when symptoms began, and the blood-draw date. Save a dated photo of any expanding rash. The chance of finding antibodies changes quickly in the first weeks.
Bring the original report from any past Lyme test and your treatment dates. Antibodies can remain for years, so a new positive may come from an older infection. Also record antibiotics taken before testing. Early treatment can stop antibodies from appearing.
Tell the clinician about pregnancy, immune problems, transplant care, or medicines that weaken antibody production. Also report conditions that may cause a false positive. These include relapsing fever, syphilis, rheumatoid arthritis, Epstein-Barr virus infection, and lupus.
This blood antibody test usually needs no fasting or special diet. If you're having other blood tests, follow the collection site's instructions. Do not stop medicine, start antibiotics, fast, or take herbs or supplements to try to change the result.
Start with why the test was ordered
Know where you were exposed, any rash or objective sign, when illness began, past Lyme history, and what decision the test should change. Low-probability testing creates more misleading positives.
Identify both tiers
Save the first assay and its call, the second assay or immunoblot, IgM and IgG when reported, and the laboratory's overall result.
Use timing before labels
An early negative can precede a detectable antibody response. An IgM-only result after the first month should not be used as evidence of recent infection without careful review.
Separate exposure from current illness
A complete positive result shows Borrelia antibodies. It may come from a recent or older infection. The result cannot tell whether bacteria remain or measure a cure.
How to read a complete Lyme two-tier result
Start with the laboratory's final result. Then add when the illness began, where exposure happened, current signs, earlier Lyme reports, antibiotics, and the two tests used.
Overall two-tier result negative
Overall two-tier result negative, including a negative first tier or a reactive first tier not confirmed by the second tier
The complete algorithm found no laboratory evidence of Lyme antibodies. This weighs against infection when testing was done at an appropriate time, but a very early sample can be negative before antibodies develop. Use the illness date and clinical findings to decide whether repeat testing is appropriate.
First-tier ELISA positive or equivocal, second tier pending
First-tier EIA or ELISA positive or equivocal while the required second-tier result is pending
This is an incomplete result, not a Lyme diagnosis. Wait for the follow-up immunoblot or second immunoassay. Then go by the lab's overall interpretation, not the first index value.
IgM detected without IgG
Complete result with IgM detected and IgG not detected
This can support recent infection when symptoms began within 30 days and the exposure and illness fit. After 30 days, CDC says to ignore the IgM result because false-positive or persistent IgM becomes a larger concern. Review the exact algorithm and timing.
IgG or total-antibody two-tier result positive
Complete two-tier result positive for IgG or for total antibodies by the approved algorithm
This can reflect a recent or older infection when the exposure and illness fit. Past Lyme results and current signs help show which is more likely. Antibody levels are not a test of cure.
A typical expanding rash can arrive before antibodies
IDSA says a clinician can diagnose a matching erythema migrans rash after likely exposure in an area with Lyme disease. This is the expanding rash linked to early Lyme disease. Waiting for antibodies can delay care.
See research details
These rows separate the two-tier rule, early timing, 2024 to 2026 assay comparisons, persistent positives, and age and sex context.
Read the laboratory's overall reported result. A first-tier ELISA, a private band list, or an isolated raw index can't diagnose Lyme disease.
One early negative can't override a typical expanding rash or another strong visible or measurable sign. Let the clinician decide whether to diagnose from the exam and history, retest, or take another route.
These selected biobank findings reinforce the early window problem and method differences. They do not make a negative result meaningless later in illness or replace a clinical assessment. The paper also reports relevant financial relationships, which should remain visible when weighing it.
A discordant result can reflect the assay pair, especially for IgM. Keep the test platform and complete algorithm with the report, and don't compare single values across labs.
Commercial assay pairs are not interchangeable. The 30-day symptom rule and the laboratory's approved pair belong in the interpretation.
A positive report in an older adult or anyone previously positive is not automatically a new infection. Bring the earlier report, treatment history, and current objective findings.
Use the cutoff and approved testing algorithm for that Lyme test. Give the doctor your age, exposure history, earlier positive Lyme results, pregnancy status, and current symptoms.
Keep a clear symptom and exposure record
Keep clear notes about the possible exposure and your symptoms.
Keep the rash and exposure timeline
Photograph an expanding rash with the date and an object that shows its size. Record where you were and when someone found or removed the tick. Add how long it may have been attached and when each symptom began.
Use tick prevention for the next exposure
After time outdoors, check the whole body for ticks, shower soon after returning, examine gear and pets, and dry clothing on high heat when appropriate. Prevention doesn't change this blood result, but it lowers the chance of another bite.
Keep the complete report
Save both tiers, every IgM and IgG call, the assay names, the final interpretation, symptom duration, prior Lyme results, antibiotics, and what the clinician concluded. A screenshot of one positive first-tier line is not enough for the next appointment.
Investigate persistent symptoms by what they are
If brain fog or fatigue continues, ask about other common causes. These include sleep, medicines, migraine, mood, iron, B12, thyroid, glucose, blood counts, and blood-pressure changes when standing. Still ask, even with an old antibody result.
Complete the two-tier Lyme algorithm before considering treatment
A reactive initial screen is no reason to start leftover or online antibiotics, herbal antimicrobials, binders, detox products, fasting, restrictive diets, or high-dose supplements. Finish the approved algorithm and use the clinical assessment.
Get urgent medical help for fainting, chest pain, severe trouble breathing, or a very slow or irregular heartbeat. Also get help for a new facial droop, severe headache with a stiff neck, weakness, numbness, confusion, trouble walking, or a fast-worsening illness. Do not wait for a Lyme result.
What to save before the next appointment
Keep these together
- First-tier assay and call, second-tier assay or immunoblot, IgM and IgG calls, raw value and cutoff if shown, laboratory, collection date, and final combined interpretation.
- Tick bite or removal date, if known, and how long the tick may have been attached. Add the exposure place, first symptom date, rash photos, and any nerve, heart, skin, or joint findings.
- Prior Lyme reports, diagnosis and treatment dates, antibiotics before this sample, and whether the current question is a first infection, possible reinfection, or persistent symptoms.
- Pregnancy, immune deficiency, B-cell-depleting or immune-suppressing treatment, transplant care, blood products, immunoglobulin treatment, and cross-reactive conditions when relevant.
- Repeat plan, specialist plan, other tick-borne tests, nearby CBC or inflammation results, and the exact decision the result changed.
Question for the visit
“Ask whether the complete FDA-cleared two-tier result fits the exposure, objective findings, symptom timing, prior Lyme history, and 30-day IgM rule, and what decision it should change.”
Sources for Lyme EIA/ELISA Two-Tier Antibody Test
Guide sections: Current US two-tier rule; Early timing can beat the antibody test; Children and teenagers; Immune suppression and antibody treatment; Keep the rash and exposure timeline; Investigate persistent symptoms by what they are; Complete the two-tier Lyme algorithm before considering treatment
Lyme disease testing and diagnosis.
Guide sections: Current US two-tier rule; Early timing can beat the antibody test; Keep the complete report
FDA clearance of new indications for existing Lyme disease tests.
Guide sections: Early timing can beat the antibody test; Children and teenagers; Immune suppression and antibody treatment
Guide sections: Complete the two-tier Lyme algorithm before considering treatment
Lyme Disease Serology, Serum.
Evaluation of standard and modified two-tiered testing algorithms using well-characterized early Lyme disease samples.
Performance of two modified two-tier algorithms for the serologic diagnosis of Lyme disease.
Comparison of 2 Sets of Immunoassays Used in Modified 2-Tiered Testing Algorithms for the Diagnosis of Lyme Disease.
Lyme Disease Testing Practices, Wisconsin, USA, 2016-2019.
Sex- and Age-Specific Lyme Disease Testing Patterns in the United States, 2019 and 2022.
Guide sections: Pregnancy and breastfeeding
Guide sections: Use tick prevention for the next exposure
See each claim's sources
procedure
CDC recommends a complete two-step Lyme antibody algorithm using FDA-cleared assays; standard testing uses EIA then immunoblot, while modified testing uses two different EIAs.interpretation
Lyme serology may be falsely negative in the first four to six weeks, and CDC says positive IgM should be disregarded when illness has lasted more than 30 days.limitation
Horn 2026 found low initial-draw sensitivity and meaningful algorithm differences in a selected early-Lyme biobank comparison; the full sample counts, sensitivity, specificity, and cross-algorithm result are shown in the evidence table.limitation
Landry 2024 found substantial method-dependent disagreement after reactive Lyme screens, especially for IgM; the full first-tier and second-tier counts are shown in the evidence table.limitation
Walsh 2025 found only 58 percent overall concordance, 55 of 95 samples, between two commercial modified two-tier algorithm interpretations, with better IgM agreement when symptoms lasted less than 30 days.context
Kugeler 2025 reviewed 42,077 testing episodes among 36,984 people and found that 6 to 15 percent of people with a positive test in a study year had also tested positive in a previous year.context
A 2025 US study included 578,052 people tested in 2019 and 550,674 in 2022 and found age- and sex-associated testing patterns, but did not establish different assay cutoffs or biological targets.